Strategic Partnering
Our Ambition
At BirchBioMed, we are committed to accelerating medical innovation and elevating patient care through the power of collaboration. Our strategic partnership opportunities are crafted to build alliances that capitalize on our cutting-edge research and development in targeted therapeutic areas. We are actively seeking to engage with industry leaders and forward-thinking innovators through two distinct partnership pathways:
Announcing the Partnering Initiative of FS2 creams platform for the treatments of mild to severe skin disorders affecting hundreds of millions people in the world
BirchBioMed has developed a novel portfolio of patented topical creams formulated with Kynurenic Acid (KynA), a natural substance generated in humans. Our product, called FS2, has been expertly designed over years of research to treat mild to severe skin-related conditions, such as burns, keloid scars, hypertrophic scars and post operative scars. FS2 results in clinical settings have been spectacular and may finally provide definitive, ground-breaking solutions to treat these disorders and to significantly improve quality of life.
Recently, we also explored the potential of FS2 creams for the treatment of mature atrophic acne scars and of wrinkles & rithyds. Based on promising results, we filed for IP and are including FS2 (KynA) in the Partnering portfolio for the treament of these indications affecting millions of subjects.
We are now seeking strong, strategic Partner(s) to commercialize these products under various deal models, including global or regional exclusive license agreements, co-commercialization agreements or other more strategic types of agreements.
If you are interested in this major opportunity to further expand your business in therapeutic areas with still high unmet needs with our novel, ground-breaking solutions, please contact us at:
Susan Elliott
Chief Marketing Officer
Hervé Girsault
Chief Business Officer
Susan Elliott
Chief Marketing Officer
Hervé Girsault
Chief Business Officer
Therapeutic Market Sizes. GrandViewResearch, MarketResearchFuture, GlobeNewsWire, GlobalData.
Partnerships with Big Pharma and Specialist Pharma Companies
BirchBioMed is poised to make significant strides in the pharmaceutical landscape with its novel, potentially groundbreaking approach to treating organ fibrosis and autoimmune disorders, initially focusing on:
Organ Fibrosis Treatments
Our portfolio includes treatments specifically designed for the systemic administration of Kynurenic Acid (KynA) to combat organ fibrosis, including challenging conditions like Idiopathic Pulmonary Fibrosis. We seek partners to further develop and commercialize these promising therapies.
Autoimmune Disorder Therapies
We are pioneering a therapeutic approach tailored for autoimmune disorders such as Type 1 Diabetes and Alopecia Areata. This strategy combines the systemic administration of KynA with a one-time delivery of APCs. We are interested in opening discussions with firms looking to expand into or enhance their portfolios in innovative autoimmune treatments.
We are committed to bringing these novel treatments to market, enhancing patient outcomes globally. Companies interested in exploring these opportunities are encouraged to contact us.
Partner with us.
BirchBioMed is looking to engage with partners who have a strong interest in developing cutting-edge treatments and who are well-positioned to help bring these therapies to a global market. If this aligns with your company’s interests, BirchBioMed would welcome the opportunity to discuss potential collaboration.
Contact:
Hervé Girsault
herve.girsault@birchbiomed.com